Patents by Inventor Scott Savage

Scott Savage has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • KINASE MODULATORS AND METHODS OF USE THEREOF
    Publication number: 20230373985
    Abstract: The present invention relates to novel compounds that modulate the activity of one or more kinases, such as TYK2 or mutants thereof. The compounds, which may be kinase inhibitors or activators, are useful for treating autoimmune diseases, such as, such as psoriasis, lupus, multiple sclerosis, and inflammatory bowel disease.
    Type: Application
    Filed: July 12, 2021
    Publication date: November 23, 2023
    Inventors: Roland KOESTLER, Nasser Yehia, Jean Tassel, Marcus Wegmann, Federico Medda, Patricia Perez-Gallan, Christiane Gilch, Michael Thormann, Andreas Treml, Michael Almstetter, Zhonghua Pei, Scott Savage
  • POLYMORPHS AND SOLID FORMS OF (S)-2-((2-((S)-4-(DIFLUOROMETHYL)-2-OXOOXAZOLIDIN-3-YL)-5,6-DIHYDROBENZO[F]IMIDAZO[1,2-D][1,4]OXAZEPIN-9-YL)AMINO)PROPANAMIDE, AND METHODS OF PRODUCTION
    Publication number: 20230167128
    Abstract: The present invention relates to crystalline polymorph forms of (S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[ƒ]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide (GDC-0077), having the structure, Formula I: or stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, and processes of preparing the polymorph forms.
    Type: Application
    Filed: January 26, 2023
    Publication date: June 1, 2023
    Applicant: Genentech, Inc.
    Inventors: Paroma Chakravarty, Chong Han, Sean M. Kelly, Karthik Nagapudi, Scott Savage
  • Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production
    Patent number: 11591345
    Abstract: The present invention relates to crystalline polymorph forms of (S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide (GDC-0077), having the structure, Formula I: or stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, and processes of preparing the polymorph forms.
    Type: Grant
    Filed: May 15, 2020
    Date of Patent: February 28, 2023
    Assignee: Genentech, Inc.
    Inventors: Paroma Chakravarty, Chong Han, Sean M. Kelly, Karthik Nagapudi, Scott Savage
  • PROCESS FOR THE PREPARATION OF N-((1R,2S,5R)-5-(TERT-BUTYLAMINO)-2-((S)-3-(7-TERT-BUTYLPYRAZOLO[1,5-A][1,3,5]TRIAZIN-4-YLAMINO)-2-OXOPYRROLIDIN-1-YL)CYCLOHEXYL)ACETAMIDE
    Publication number: 20220177482
    Abstract: The invention generally relates to an improved process for the preparation of N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, as well as novel intermediates employed in the process, which may be useful for the treatment of cancer.
    Type: Application
    Filed: February 22, 2022
    Publication date: June 9, 2022
    Inventors: Burcu Selin Aytar, Alina Borovika, Collin Chan, Joerg Deerberg, Nathan R. Domagalski, Martin D. Eastgate, Yu Fan, Michael David Bengt Fenster, Robert V. Forest, Francisco Gonzalez-Bobes, Rebecca A. Green, Matthew R. Hickey, Nathaniel David Kopp, Thomas E. La Cruz, Kathleen Lauser, Hong Geun Lee, David K. Leahy, Helen Y. Luo, Thomas M. Razler, Scott A. Savage, Chris Sfouggatakis, Maxime C.D. Soumeillant, Serge Zaretsky, Bin Zheng, Ye Zhu
  • Process for the preparation of N-((1R,2S,5R)-5-(-butylamino)-2-((S)-3-(7--butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrroldin-1-yl)cyclohexyl)acetamide
    Patent number: 11254679
    Abstract: The invention generally relates to an improved process for the preparation of N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, as well as novel intermediates employed in the process, which may be useful for the treatment of cancer.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: February 22, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Burcu Selin Aytar, Alina Borovika, Collin Chan, Joerg Deerberg, Nathan R. Domagalski, Martin D. Eastgate, Yu Fan, Michael David Bengt Fenster, Robert V. Forest, Francisco Gonzalez-Bobes, Rebecca A. Green, Matthew R. Hickey, Nathaniel David Kopp, Thomas E. La Cruz, Kathleen Lauser, Hong Geun Lee, David K. Leahy, Helen Y. Luo, Thomas M. Razler, Scott A. Savage, Chris Sfouggatakis, Maxime C. D. Soumeillant, Serge Zaretsky, Bin Zheng, Ye Zhu
  • Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production
    Patent number: 11028100
    Abstract: The present invention relates to crystalline polymorph forms of (S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide (GDC-0077), having the structure, Formula I: or stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, and processes of preparing the polymorph forms.
    Type: Grant
    Filed: May 15, 2020
    Date of Patent: June 8, 2021
    Assignee: Genentech, Inc.
    Inventors: Paroma Chakravarty, Chong Han, Sean M. Kelly, Karthik Nagapudi, Scott Savage
  • POLYMORPHS AND SOLID FORMS OF (S)-2-((2-((S)-4-(DIFLUOROMETHYL)-2-OXOOXAZOLIDIN-3-YL)-5,6-DIHYDROBENZO[F]IMIDAZO[1,2-D][1,4]OXAZEPIN-9-YL)AMINO)PROPANAMIDE, AND METHODS OF PRODUCTION
    Publication number: 20210094970
    Abstract: The present invention relates to crystalline polymorph forms of (S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide (GDC-0077), having the structure, Formula I: or stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, and processes of preparing the polymorph forms.
    Type: Application
    Filed: May 15, 2020
    Publication date: April 1, 2021
    Applicant: Genentech, Inc.
    Inventors: Paroma Chakravarty, Chong Han, Sean M. Kelly, Karthik Nagapudi, Scott Savage
  • USE OF NEUTROPHIL ELASTASE INHIBITORS IN LIVER DISEASE
    Publication number: 20210069192
    Abstract: The invention relates to methods for treating chronic liver disease, in particular nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), with neutrophil elastase inhibitors. The invention further relates to pharmaceutical compositions comprising neutrophil elastase inhibitors.
    Type: Application
    Filed: September 21, 2020
    Publication date: March 11, 2021
    Applicant: pH Pharma Co., Ltd.
    Inventors: Sanjeev SATYAL, Brian ROBERTS, Xueyan WANG, Scott SAVAGE, Hoyoung HUH
  • POLYMORPHS AND SOLID FORMS OF (S)-2-((2-((S)-4-(DIFLUOROMETHYL)-2-OXOOXAZOLIDIN-3-YL)-5,6-DIHYDROBENZO[F]IMIDAZO[1,2-D][1,4]OXAZEPIN-9-YL)AMINO)PROPANAMIDE, AND METHODS OF PRODUCTION
    Publication number: 20200399286
    Abstract: The present invention relates to crystalline polymorph forms of (S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide (GDC-0077), having the structure, Formula I: or stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, and processes of preparing the polymorph forms.
    Type: Application
    Filed: May 15, 2020
    Publication date: December 24, 2020
    Applicant: Genentech, Inc.
    Inventors: Paroma Chakravarty, Chong Han, Sean M. Kelly, Karthik Nagapudi, Scott Savage
  • Process for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds
    Patent number: 10870626
    Abstract: The present disclosure relates to processes for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds, and more particularly relates to processes for preparing (R)-4-(5-methyl-7-oxo-6,7-dihydro-5H-cyclopenta[d] pyrimidin-4-yl)piperazine and N-protected derivatives thereof, which may be used as an intermediate in the synthesis of Ipatasertib (i.e., (S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)-propan-1-one). The present disclosure additionally relates to various compounds that are intermediates employed in these processes.
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: December 22, 2020
    Assignees: F. Hoffman-La Roche AG, Genentech, Inc.
    Inventors: Francis Gosselin, Chong Han, Hans Iding, Reinhard Reents, Scott Savage, Beat Wirz
  • Use of neutrophil elastase inhibitors in liver disease
    Patent number: 10806735
    Abstract: The invention relates to methods for treating chronic liver disease, in particular nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), with neutrophil elastase inhibitors. The invention further relates to pharmaceutical compositions comprising neutrophil elastase inhibitors.
    Type: Grant
    Filed: April 22, 2019
    Date of Patent: October 20, 2020
    Assignee: pH Pharma Co., Ltd.
    Inventors: Sanjeev Satyal, Brian Roberts, Xueyan Wang, Scott Savage, Hoyoung Huh
  • Process for the preparation of (S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[F]imidazo[1,2-D][1,4]oxazepin-9-yl)amino) propanamide
    Patent number: 10781219
    Abstract: Methods of making benzoxazepin oxazolidinone compounds as well as synthetic intermediates are described, including compound 18, having the structure:
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: September 22, 2020
    Assignee: Genentech, Inc.
    Inventors: Francis Gosselin, Chong Han, Theresa Cravillion, Sean M. Kelly, Scott Savage
  • PROCESS FOR THE PREPARATION OF N-((1R,2S,5R)-5-(TERT-BUTYLAMINO)-2-((S)-3-(7-TERT-BUTYLPYRAZOLO[1,5-A][1,3,5]TRIAZIN-4-YLAMINO)-2-OXOPYRROLIDIN-1-YL)CYCLOHEXYL)ACETAMIDE
    Publication number: 20200223852
    Abstract: The invention generally relates to an improved process for the preparation of N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolodin-1-yl)cyclohexyl)acetamide, as well as novel intermediates employed in the process, which may be useful for the treatment of cancer.
    Type: Application
    Filed: July 19, 2018
    Publication date: July 16, 2020
    Inventors: Burcu Selin Aytar, Alina Borovika, Collin Chan, Joerg Deerberg, Nathan R. Domagalski, Martin D. Eastgate, Yu Fan, Michael David Bengt Fenster, Robert V. Forest, Francisco Gonzalez-Bobes, Rebecca A. Green, Matthew R. Hickey, Nathaniel David Kopp, Thomas E. La Cruz, Kathleen Lauser, Hong Geun Lee, David K. Leahy, Helen Y. Luo, Thomas M. Razler, Scott A. Savage, Chris Sfouggatakis, Maxime C.D. Soumeillant, Serge Zaretsky, Bin Zheng, Ye Zhu
  • PROCESS FOR PREPARING (CYCLOPENTYL[d]PYRIMIDIN-4-YL)PIPERAZINE COMPOUNDS
    Publication number: 20200010428
    Abstract: The present disclosure relates to processes for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds, and more particularly relates to processes for preparing (R)-4-(5-methyl-7-oxo-6,7-dihydro-5H-cyclopenta[d] pyrimidin-4-yl)piperazine and N-protected derivatives thereof, which may be used as an intermediate in the synthesis of Ipatasertib (i.e., (S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)-propan-1-one). The present disclosure additionally relates to various compounds that are intermediates employed in these processes.
    Type: Application
    Filed: September 18, 2019
    Publication date: January 9, 2020
    Inventors: Francis Gosselin, Chong Han, Hans Iding, Reinhard Reents, Scott Savage, Beat Wirz
  • Hepatitis C virus inhibitors
    Patent number: 10494400
    Abstract: The present disclosure relates to methods for making asunaprevir, useful treatment of Hepatitis C virus (HCV) infection, and its intermediates.
    Type: Grant
    Filed: June 23, 2015
    Date of Patent: December 3, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Scott A. Savage, Nathan R. Domagalski, Brendan Mack, Purushotham Vemishetti, Yuping Qiu, Michael Fenster, Daniel M. Hallow, Glenn Ferreira, Amanda Rogers, Sha Lou, Lindsay Hobson
  • Process for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds
    Patent number: 10457648
    Abstract: The present disclosure relates to processes for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds, and more particularly relates to processes for preparing (R)-4-(5-methyl-7-oxo-6,7-dihydro-5H-cyclopenta[d] pyrimidin-4-yl)piperazine and N-protected derivatives thereof, which may be used as an intermediate in the synthesis of Ipatasertib (i.e., (S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)-propan-1-one). The present disclosure additionally relates to various compounds that are intermediates employed in these processes.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: October 29, 2019
    Assignees: GENENTECH INC., F. HOFFMANN-LA ROCHE AG
    Inventors: Francis Gosselin, Chong Han, Hans Iding, Reinhard Reents, Scott Savage, Beat Wirz
  • USE OF NEUTROPHIL ELASTASE INHIBITORS IN LIVER DISEASE
    Publication number: 20190321364
    Abstract: The invention relates to methods for treating chronic liver disease, in particular nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), with neutrophil elastase inhibitors. The invention further relates to pharmaceutical compositions comprising neutrophil elastase inhibitors.
    Type: Application
    Filed: April 22, 2019
    Publication date: October 24, 2019
    Applicant: pH Pharma Co., Ltd.
    Inventors: Sanjeev Satyal, Brian Roberts, Xueyan Wang, Scott Savage, Hoyoung Huh
  • PROCESS FOR THE PREPARATION OF (S)-2-((2-((S)-4-(DIFLUOROMETHYL)-2-OXOOXAZOLIDIN-3-YL)-5,6-DIHYDROBENZO[F]IMIDAZO[1,2-D][1,4]OXAZEPIN-9-YL)AMINO) PROP AN AMIDE
    Publication number: 20190292201
    Abstract: Methods of making benzoxazepin oxazolidinone compounds as well as synthetic intermediates are described, including compound 18, having the structure:
    Type: Application
    Filed: June 14, 2019
    Publication date: September 26, 2019
    Applicant: Genentech, Inc.
    Inventors: Francis GOSSELIN, Chong HAN, Theresa CRAVILLION, Sean M. KELLY, Scott SAVAGE
  • Methods of producing an HIV maturation inhibitor
    Patent number: 10221208
    Abstract: A method for producing HIV maturation inhibitor compound is set forth using betulin as starting material, and utilizing Lossen rearrangement techniques.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: March 5, 2019
    Assignee: VIIV HEALTHCARE UK (NO.4) LIMITED
    Inventors: Adrian Ortiz, Maxime Soumeillant, Scott A. Savage, Neil A. Strotman, Martin D. Eastgate, Matthew W. Haley, Jeanne Ho, Jeffrey A. Nye, Zhongmin Xu, Susanne Kiau, Tamas Benkovics, Yichen Tan
  • POLYMORPHS AND SOLID FORMS OF (S)-2-((2-((S)-4-(DIFLUOROMETHYL)-2-OXOOXAZOLIDIN-3-YL)-5,6-DIHYDROBENZO[F]IMIDAZO[1,2-D][1,4]OXAZEPIN-9-YL)AMINO)PROPANAMIDE, AND METHODS OF PRODUCTION
    Publication number: 20180339997
    Abstract: The present invention relates to crystalline polymorph forms of (S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide (GDC-0077), having the structure, Formula I: or stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, and processes of preparing the polymorph forms.
    Type: Application
    Filed: April 26, 2018
    Publication date: November 29, 2018
    Applicant: Genentech, Inc.
    Inventors: Paroma Chakravarty, Chong Han, Sean M. Kelly, Karthik Nagapudi, Scott Savage